The MUSTT trial - Preventing sudden death in coronary cardiomyopathy: Implantable defibrillators lead the way

The Multicenter Unsustained Tachycardia Trial (MUSTT) demonstrated that ele ctrophysiologic testing (EP)-guided therapy significantly reduces arrhythmi c death and cardiac arrest in patients with coronary artery disease, a left ventricular ejection fraction of 40% or less, nonsustained ventricular tac hycardia, and inducible ventricular arrhythmia on EP testing-but only if th e therapy includes an implantable defibrillator. All patients who meet the MUSTT inclusion criteria should undergo an EP test and if positive, should undergo defibrillator implantation.